IPG2019 Program

  Print Full program

Wednesday, September 4

Time Session/Lecture info
Day 1: Geroscience — Addressing the root causes of aging-related diseases
Registration and gathering
Opening remarks:
Stephanie Lederman, Executive Director, American Federation for Aging Research (AFAR)
Nir Barzilai, Albert Einstein College of Medicine
Sami Sagol, The Sagol Institute for Longevity Research
Alon Chen, President Elect, Weizmann Institute of Science
Principles of Geroscience
Chair: Ron Kohanski 
S. Jay Olshansky, School of Public Health at the University of Illinois at Chicago
From Lifespan to Healthspan
Life extension without health extension would be harmful should it come to pass -- unfortunately our current medical model of treating one disease at a time is heading us all in that direction. The solution is to attack the underlying risk factor for all fatal and disabling diseases -- the biological process of aging; yielding a new form of primary prevention in the 21st century.
Ronald Kohanski, Division of Aging Biology at the National Institute on Aging, NIH
Concepts and Perspectives in Geroscience
Outline concepts for the hallmarks of aging, provide examples of the intersection between these hallmarks and other risk factors for morbidity, and conclude with suggestions about leveraging these findings in the development of anti-aging therapies that emerge from Geroscience.
Steve Austad, Department of Biology at the University of Alabama at Birmingham
The surprising impact of sex on geroscience research
Considerable success has already attended geroscientific research in laboratory mice. This talk will update that success and will also consider an emerging pattern which is that sex differences in response to senescence-retarding interventions seem to be common.
Nir Barzilai, Institute for Aging Research at the Albert Einstein College of Medicine
Improving health span of elderly: Not a science fiction anymore.
Differences in biological and chronological aging is exemplified in centenarians who have extended life span, contracted morbidity and functional genotypes in known pathways of aging. We have made progress in launching a large clinical study that aims to prove aging can be targeted but also get FDA approval, so biotech and pharma will develop better drugs and their combination to realize our potential health span.
Cellular and Molecular Biology of Aging, Basic and Translational Aspects
Chair: Haim Cohen 
David Sinclair, Genetics Department at Harvard Medical School, Boston
Preventing and reversing Waddington drift during aging
Increasing evidence points to aging a loss of information that is recoverable. I will present new approaches to modulating aging in the forward and reverse directions
Haim Cohen, Bar Ilan University
"Keep your energy": SIRT6 and frailty
Mice over-expressing SIRT6 (MOSES mice) have extended lifespan along with significant improvement of their healthspan. Old age related frailty typically manifesting as a syndrome of a constellation of weakness, slowness, reduced activity, low energy and unintended weight loss. Here we will describe the mechanisms underlying SIRT6 positive effects on healthy aging primarily by providing the required energy at old age and slowing aging related frailty.
Valery Krizhanovsky, Weizmann Institute of Science
Senescent cells as drivers of aging and age-related diseases
Cellular senescence is one of the hallmarks of aging. Senescent cells accumulate with age and contribute to organismal aging and age-related pathologies. We reveled that immune surveillance of senescent cells plays a critical role in restricting this accumulation. Pharmacological elimination of senescent cells might prevent the deleterious consequences of their accumulation.
Lunch and Poster Session
Genetics, Epigenetics, Diagnostic and therapeutic aspects
Chair: Gil Atzmon 
Steve Horvath, Human genetics, School of Public Health. University of California at Los Angeles
Epigenetic aging clocks for mammals and human clinical trials
Recent epigenetic aging clocks are highly predictive of human lifespan and health span. These epigenetic biomarkers are ready for human clinical trials of anti-aging interventions. Analogous epigenetic clocks can be defined for other mammalian species including mice, dogs, bats, and marine mammals.
Gil Atzmon, Haifa University
Survival of the fittest
Epigenetic changes associated with aging could serve as markers for healthy life span, and may represent one of the central mechanisms of gene regulation by which many aging process are buffered, and therefore facilitate healthy lifespan.
Liran Shlush, Weizmann Institute of Science
Early diagnosis and treatment of AML
Acute Myeloid Leukemia (AML) is a deadly disease. Recent studies suggest that AML can be predicted many years before its current diagnosis. New therapies focused on the early stages of AML are under development.
Ido Wolf, Tel Aviv University
The hormone klotho: a novel connection between aging and cancer
The hormone klotho is a potent regulator of aging-related characteristics and low levels of it are associated with frailty and shortened survival. We have identified klotho as a potent tumor suppressor and recent studies from our lab indicate it as a regulator of mitochondrial activity. These observations indicate klotho as novel link between aging and cancer.


Registration is free but required. 
Spaces are limited!

Organizing committee

Prof. Nir Barzilai
Prof. Gabi Barbash
Dr. Ilia Stambler
Prof. Valery Krizhanovsky

Coordinator & Accessibility Issues

Reut Hershenhoren